This review discusses the limitations of current anticoagulants like warfarin and heparin, and explores new investigational oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Warfarin and heparin limitations warrant individualized use; leaves open the role of investigational oral anticoagulants pending trials.
The risk of bleeding, narrow therapeutic index, and need for routine monitoring make oral anticoagulation with warfarin a less than ideal oral anticoagulant. Intravenous therapies such as heparin are not orally bioavailable and have a narrow therapeutic index and high risk of bleeding. New oral antico agulants currently under investigation may have more ideal characteristics for long-term administration. The mechanism of thrombogenesis, limitations of current therapy, and new investigational oral anticoagulants are discussed.
No takes yet. Share an insight, caveat, or question.
Katie M. Greenlee (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: